Chemotherapy of Advanced Non-Hodgkin Lymphomas: A Report of 35 Cases

1982 ◽  
Vol 68 (4) ◽  
pp. 307-311
Author(s):  
Gualtiero Büchi ◽  
Umberto Mazza ◽  
Clara Camaschella ◽  
Giuseppe Saglio ◽  
Giovanna Rege Cambrin ◽  
...  
Keyword(s):  
Complete Remission ◽  
Median Survival ◽  
Combination Chemotherapy ◽  
Tumor Response ◽  
Stage Iii ◽  
Chop Regimen ◽  
The Difference ◽  
Histologic Types ◽  
Total Remission

Thirty-five patients with stage III and IV non-Hodgkin lymphomas, classified according to Lennert have been treated by combination chemotherapy (CVP). Total remission (complete plus partial) was obtained in 68.5% of the cases and complete remission in 28.5%; 73% of the favorable types and 55% of the unfavorable histologic types achieved tumor response: the difference was not statistically significant, perhaps because of the limited number of cases. Median survival was 14 months for the unfavorable histologic types and 28 months for the favorable types; longer survivals were obtained in patients who achieved complete remission. CHOP regimen after CVP in patients refractory to this type of treatment was not satisfactory in our patients.

Correlation of tumor response and survival in advanced NSCLC patients treated with paclitaxel plus carboplatin (PC) versus paclitaxel plus carboplatin plus gemcitabine (PCG)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7650-7650
Author(s):  
A. Paccagnella ◽  
F. Oniga ◽  
A. Bearz ◽  
A. Favaretto ◽  
F. Barbieri ◽  
...  
Keyword(s):  
Median Survival ◽  
Advanced Nsclc ◽  
Tumor Response ◽  
Cox Model ◽  
Early Death ◽  
Survival Difference ◽  
The Difference ◽  
Similar Survival ◽  
Cox Analysis ◽  
Nsclc Patients

7650 Background: We showed that PCG significantly increases both response rate (RR) (43.6% vs 20%) and median survival (10.8 mo vs 8.3 mo) over PC and that at Cox analysis, the only independent prognostic factors were PS and treatment (Paccagnella et al, J Clin Oncol 2006;24: 681–687). According to the Prentice criteria (Stat Med 1989;8: 431–440), to directly relate response and survival it is necessarily that responding patients (and non responding) of both arms have a similar survival and that the survival difference between the two arms disappear when the response factor is included in the multivariate analysis. Methods: Out of 324 pts included in the original analysis, 26 pts were not evaluable for response (early death, toxicity, refusal) before the planned response evaluation at two months and were excluded (15 pts from PC arm and 11 pts from PCG arm). The analysis however was also performed considering the non evaluable patients as non responders. Results: Overall, Responder patients had a median Survival that nearly doubled that of no responders: 14.73 mo vs 7.67 mo (HR: 0.49; CI: 0.31–0.54; P=0.000). No responder pts from PC and PCG arms had a similar survival (median 7.53 mo and 8.07 mo respectively; P= 0.96) as well as responder (CR + PR) patients (median 14.13 mo and 15.40 mo respectively; P=0.38). The principal difference between the two arms was that more than the double of patients in PCG arm responded (43.6% vs 20%) and consequently had a survival advantage of clinical relevance in comparison to patients in PC arm. When tumor response was introduced in the Cox model (as a four level variable), the difference in Overall Survival between PCG and PC changed from a significant level (HR=1.28; CI 1.00–1.63; P=0.049) to a not significant level (HR=0.99; CI: 0.76 - 1.28; P=0.97). Conclusions: To our knowledge this is the first report showing a significant direct correlation between response and survival in advanced NSCLC according to Prentice criteria. No significant financial relationships to disclose.

Combination Chemotherapy with Methotrexate, Endoxan, and Vincristine (M.E.V.) in the Treatment of non-Hodgkin's Lymphoma

1973 ◽  
Vol 59 (6) ◽  
pp. 401-408 ◽  
Author(s):  
Francesco Lauria ◽  
Michele Baccarani ◽  
Enza Barbieri ◽  
Mauro Fiacchini ◽  
Sante Tura
Keyword(s):  
Side Effects ◽  
Median Survival ◽  
Combination Chemotherapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Stage Iii ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Histiocytic Lymphoma

Twelve patients with lymphocytic lymphoma (L.L.), and 9 patients with histiocytic lymphoma (H.L.), stage III and IV, were treated as outpatients with combination chemotherapy including six courses of cyclophosphamide (Endoxan), Methotrexate, and vincristine (M.E.V. regimen). Marrow depression and side-effects were moderate. In the 12 patients with L.L., there were 6 complete remissions (C.R.), 3 incomplete remission (I.R.), and 3 partial failures (P.F.). In the 9 patients with H.L., there were 7 C.R., 1 I.R. and 1 P.F. Median survival from the end of the therapy is 7 + mos. for the L.L. patients, and 10 + mos. for H.L. patients, all patients being alive but one.

Vinblastine plus Bleomycin Continuous Infusion Chemotherapy of Stage III Testicular Carcinomas

1981 ◽  
Vol 67 (2) ◽  
pp. 117-123 ◽  
Author(s):  
Silvio Monfardini ◽  
Vittorio Fossati ◽  
Giorgio Pizzocaro ◽  
Eugenio Villa
Keyword(s):  
Complete Remission ◽  
Median Survival ◽  
Remission Rate ◽  
Drug Dosage ◽  
Stage Iii ◽  
Infusion Chemotherapy ◽  
Abdominal Disease ◽  
Testicular Carcinoma ◽  
Continuous Infusion Chemotherapy ◽  
Definition Of

Thirty-four consecutive patients with stage III testicular carcinomas were treated with vinblastine, 8 mg/m2 given in 2 fractions on day 1 and 2, followed by continuous intravenous administration of bleomycin, 15 mg/m2 in 1000 cc of 5 % glucose and distilled water over a 24-hour period for 5 successive days beginning on day 2. This cycle was repeated every 28-35 days as toxicity permitted. Complete remission occurred in 18 % and complete plus partial remission in 79 %. Only 2 of 22 patients with advanced abdominal disease achieved a complete remission. After cytoreductive surgery the complete remission rate was increased to 39 %. Median survival of complete responders at 3 years has not been reached, and it has been shown to be significantly superior to that of partial (p < 0.01) and nonresponders (p < 0.01). Toxic effects consisted mainly in severe leukopenia, stomatitis, adynamic ileum and osteoarticular pain. One drug-related death due to sepsis with agranulocytopenic fever was observed. Probably because of different patient selection, this report could not reproduce the results reported by Samuels et al. with equivalent drug dosage, but it was confirmed that this regimen is able to achieve a high overall response rate and a prolonged median survival in complete responders. The consistent success of this aggressive combination in inducing a high percentage of partial responses has opened the way for a better definition of the role of surgery for the treatment of advanced testicular carcinoma at our Institute.

Follicular large cell lymphoma: analysis and prognostic factors in 62 patients.

1984 ◽  
Vol 2 (7) ◽  
pp. 811-819 ◽  
Author(s):  
H M Kantarjian ◽  
P McLaughlin ◽  
L M Fuller ◽  
D O Dixon ◽  
B M Osborne ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Prognostic Factors ◽  
Complete Remission ◽  
Combination Chemotherapy ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Stage I ◽  
Stage Iii ◽  
Free Interval ◽  
Large Cell Lymphoma

Sixty-two patients with follicular large cell lymphoma were treated between 1973 and 1981. The overall median survival was 78 months with a five-year survival of 62%. The complete remission rate was 76%, with a median relapse-free interval of 72 months for responders. Complete remission produced a significantly longer survival than partial response and failure. Patients who tolerated therapy with an intensive doxorubicin-containing regimen had a significantly longer relapse-free interval and survival. Patients with stage I-II disease treated with radiation therapy alone had a higher relapse rate than those treated with radiation and combination chemotherapy. The addition of radiation therapy to combination chemotherapy in stage III-IV disease decreased the incidence of relapse at irradiated sites, but did not translate into improved survival. Pretreatment prognostic factors associated with poor response were thrombocytosis and stage III-IV disease; those associated with shortened survival were thrombocytosis, elevated lactic dehydrogenase level, stage III-IV disease, and bulky abdominal disease. Follicular large cell lymphoma is an aggressive lymphoma. Treatment should be curative in intent, and should include intensive combination chemotherapy even in stage I-II disease. Knowledge of important prognostic factors can be useful for analysis of future trials and planning therapeutic strategies.

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

2004 ◽  
Vol 14 (2) ◽  
pp. 224-228 ◽  
Author(s):  
D. S. Alberts ◽  
C. Jiang ◽  
P. Y. Liu ◽  
S. Wilczynski ◽  
M. Markman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Complete Remission ◽  
Median Survival ◽  
Phase Ii ◽  
Survival Data ◽  
Progression Free Survival ◽  
Stage Iii ◽  
Consolidation Therapy ◽  
First Line Therapy

ObjectiveThis report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy.MethodsPatients who enrolled in the SWOG 9326 study from September 1993 to July 1997 were required to have documented cCR from stage III ovarian cancer following front-line platinum-based therapy. Treatment consisted of 6 months of oral altretamine at 260 mg/m2/day for 14 consecutive days of a 28-day cycle.ResultsNinety-seven of 112 enrolled patients were evaluable for efficacy. This report presents median 6.2-year follow-up, dating from study registration. Median PFS was 28 (95% CI: 19–43) months. Median PFS for patients with optimal disease was 45 (95% CI: 27–48) months and for patients with suboptimal disease was 17 (95% CI: 12–26) months. Twenty-six of 61 (43%) patients with optimally debulked lesions and 5 of 36 (14%) patients with suboptimally debulked lesions remained disease free. Median survival of patients with optimally debulked disease has not been reached; median survival of patients with suboptimally debulked disease was 39 (95% CI: 19–51) months. No treatment-related adverse events were reported during the follow-up period.ConclusionsConsolidation therapy with oral altretamine was generally well tolerated and associated with prolonged progression-free and overall survival in the Phase II setting.

scholarly journals Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma

Blood ◽  
1974 ◽  
Vol 43 (2) ◽  
pp. 181-189 ◽  
Author(s):  
Philip S. Schein ◽  
Bruce A. Chabner ◽  
George P. Canellos ◽  
Robert C. Young ◽  
Costan Berard ◽  
...  
Keyword(s):  
Complete Remission ◽  
Median Survival ◽  
Combination Chemotherapy ◽  
Hodgkin’S Lymphoma ◽  
Disease Free Survival ◽  
Hodgkin's Lymphoma ◽  
Free Survival ◽  
Non Hodgkin's Lymphoma ◽  
Well Differentiated ◽  
Disease Free

Abstract The evaluation of the results of CVP and MOPP chemotherapy in 80 patients with advanced stages of non-Hodgkin’s lymphoma indicates that 36 (45%) achieved a complete remission. Twenty-eight per cent of the entire group of patients remain free of disease for periods ranging from 4 mo to over 7 yr, with a projected median duration of complete remission of 3½ yr. Significant differences in prognosis relative to histologic categories were found. Well-differentiated and nodular histology were positive determinants for improved median survival, confirming the over-all clinical validity of the Rappaport classification system for the non-Hodgkin’s lymphomas. The median survival for patients in the most clinically aggressive subgroups with diffuse histology is inferior to those with nodular patterns or well-differentiated cells. In this study it was demonstrated that it was possible to achieve a significant number of complete remissions even in the most aggressive histologic subgroups using combination chemotherapy, and these responses can be correlated with an extended disease-free survival without further therapy.

Treatment outcome and prognostic factors for primary nasal lymphoma.

1995 ◽  
Vol 13 (3) ◽  
pp. 666-670 ◽  
Author(s):  
R Liang ◽  
D Todd ◽  
T K Chan ◽  
E Chiu ◽  
A Lie ◽  
...  
Keyword(s):  
T Cell ◽  
Complete Remission ◽  
Combination Chemotherapy ◽  
Disease Free Survival ◽  
Stage I ◽  
Stage Iii ◽  
Chinese Patients ◽  
Low Grade ◽  
Bulky Disease ◽  
Nasal Lymphoma

PURPOSE To report our experience managing a large series of Chinese patients with primary nasal lymphoma. PATIENTS AND METHODS From January 1975 to December 1993, 100 patients (median age, 50 years) with newly diagnosed primary nasal lymphoma were studied. There were four low-grade, 62 intermediate-grade, nine high-grade, and 25 unclassifiable lymphomas. Immunophenotyping was performed in 45 patients: eight B cell, 35 T cell, and two uncertain. All cases of angiocentric lymphoma that were typed were T cell. Fifty-two patients had stage I disease, 15 had stage II, four had stage III, and 29 had stage IV. Only 15 patients had B symptoms (weight loss, night sweats, and/or fever), and 11 had bulky disease. Thirty-nine patients with clinically localized stage I and II disease received local radiotherapy alone (before 1980), and the remaining 28 stage I and II patients received combination chemotherapy followed by local radiotherapy. The 33 patients with advanced stage III and IV disease were given combination chemotherapy, and additional radiotherapy was given to five of them who had bulky local disease. RESULTS Significantly higher complete remission rates were observed in patients with early stages of disease and those without B symptoms. Superior disease-free survival after complete remission was observed in patients with stage I/II disease. Univariate factors associated with a better overall survival included age less than 60 years, stage I disease, and absence of B symptoms. Survival was significantly better in the subgroup of patients with stage I disease. CONCLUSION Patients with nasal lymphoma, especially those with advanced disease, seemed to have a poor prognosis, and their clinical outcome was not improved significantly by the use of chemotherapy instead of radiotherapy or the use of doxorubicin-containing chemotherapeutic regimens.

Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4489-4489
Author(s):  
Francisco Tripp ◽  
Enrique Báez ◽  
Elsa Ávila ◽  
Severiano Baltazar ◽  
Oscar Garcés ◽  
...  
Keyword(s):  
Complete Remission ◽  
Maintenance Therapy ◽  
Hodgkin Lymphoma ◽  
De Novo ◽  
Disease Free Survival ◽  
Chop Regimen ◽  
Non Hodgkin Lymphoma ◽  
The Difference ◽  
Therapy Studies

Abstract Introduction: Patients with aggressive NHL may respond to treatment, but 4-year DFS is < 40%. Rituximab has shown activity as monotherapy in patients even in refractory or relapsing post-MOT patients. Besides, preliminary results from maintenance therapy studies are promising. Objective: To determine if maintenance with Rituximab in first complete remission increases disease-free survival and overall survival compared to observation. Methods: A clinical trial with post-remission randomization was carried out, including patients with Aggressive Non-Hodgkin Lymphoma, stages IIb- III- IV, with ECOG 0–2, and ≥15 years old. All patients received the Rituximab + CHOP/CHOP-Like regimen during induction to remission (IR), and those with Complete Remission (CR) were randomized to receive rituximab-based maintenance therapy biannually (2 x 375 mg/sc) vs observation. Results: 217 patients have been enrolled to IR, age 52±14 years old, 114 (52.5%) masculine, 174 of them (80.2%) presented remission; 149 CR, 25 PR. Two (0.9%) patients showed stable disease, 25 (11.5%) developed disease progression, and 16 (7.4%) died. Out of the 174 patients with remission, 96 patients have received maintenance therapy for over 6 months, 45 in the rituximab group, and 51 in the observation group, with a median follow-up of 14.4 months (pt 25– 75, 7.74 – 21.88 months). To date only 1 patient per group had a progress and none has died. During IR -considering the maximum toxicity developed per patient -, acute toxicity was remarkable: fever I, II in 13%, III–IV 1%, and chills I, II 8.2%, III 1%. And not acute: anemia I,II 54%, III 1.9, IV 1.4%, neutropenia I,II 46.1%, III 18.4, IV 2.8% and infection I,II 16.4%, III 1.0%, and IV 1.4%. Discussion: Overall response to Rituximab + CHOP regimen is very good (80.2%), and to date 96 patients included in maintenance therapy with a median follow-up of 14.4 months, the difference between the groups is not evident yet; therefore, surveillance should be continued.

Prognosis after Surgical Excision of Canine Fibrous Connective Tissue Sarcomas

1980 ◽  
Vol 17 (5) ◽  
pp. 581-588 ◽  
Author(s):  
D. E. Bostock ◽  
M. T. Dye
Keyword(s):  
Connective Tissue ◽  
Survival Time ◽  
Mitotic Index ◽  
Median Survival ◽  
Median Survival Time ◽  
Surgical Excision ◽  
Fibrous Connective Tissue ◽  
Recurrence Rates ◽  
The Difference ◽  
Histologic Types

One hundred eighty seven dogs from which fibrous connective tissue sarcomas had been excised were studied until death or for at least 3 years after surgery. Dogs with a skin fibrosarcoma had a median survival time of 80 weeks, compared with 140 weeks for animals with haemangiopericytoma in similar sites, this difference being statistically significant. However, the difference in survival time between the two histologic types disappeared when tumours with a similar mitotic index were compared. Dogs with a tumour of mitotic index 9 or more had a median survival time of 49 weeks, compared with 118 weeks for those with a tumour of mitotic index less than 9, regardless of tumour morphology. Tumour recurrence rates of 62% and 25% respectively for the two groups were also significantly different.

Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Milani ◽  
L Obici ◽  
R Mussinelli ◽  
M Basset ◽  
G Manfrinato ◽  
...  
Keyword(s):  
Natural History ◽  
Median Survival ◽  
Troponin I ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Wild Type ◽  
Staging Systems ◽  
Significant Difference ◽  
History Of

Abstract Background Cardiac wild type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, is an increasingly recognized, progressive, and fatal cardiomyopathy. Two biomarkers staging systems were proposed based on NT-proBNP (in both cases) and troponin or estimated glomerular filtration rate, that are able to predict survival in this population. The availability of novel effective treatments requires large studies to describe the natural history of the disease in different populations. Objective To describe the natural history of the disease in a large, prospective, national series. Methods Starting in 2007, we protocolized data collection in all the patients diagnosed at our center (n=400 up to 7/2019). Results The referrals to our center increased over time: 5 cases (1%) between 2007–2009, 33 (9%) in 2010–2012, 90 (22%) in 2013–2015 and 272 (68%) in 2016–2019. Median age was 76 years [interquartile range (IQR): 71–80 years] and 372 patients (93%) were males. One hundred and seventy-three (43%) had atrial fibrillation, 63 (15%) had a history of ischemic cardiomyopathy and 64 (15%) underwent pacemaker or ICD implantation. NYHA class was I in 58 subjects (16%), II in 225 (63%) and III in 74 (21%). Median NT-proBNP was 3064 ng/L (IQR: 1817–5579 ng/L), troponin I 0.096 ng/mL (IQR: 0.063–0.158 ng/mL), eGFR 62 mL/min (IQR: 50–78 mL/min). Median IVS was 17 mm (IQR: 15–19 mm), PW 16 mm (IQR: 14–18 mm) and EF 53% (IQR: 45–57%). One-hundred and forty-eight subjects (37%) had a concomitant monoclonal component in serum and/or urine and/or an abnormal free light chain ratio. In these patients, the diagnosis was confirmed by immunoelectron microscopy or mass spectrometry. In 252 (63%) the diagnosis was based on bone scintigraphy. DNA analysis for amyloidogenic mutations in transthyretin and apolipoprotein A-I genes was negative in all subjects. The median survival of the whole cohort was 59 months. The Mayo Clinic staging based on NT-proBNP (cutoff: 3000 ng/L) and troponin I (cutoff: 0.1 ng/mL) discriminated 3 different groups [stage I: 131 (35%), stage II: 123 (32%) and stage III: 127 (33%)] with different survival between stage I and II (median 86 vs. 81 months, P=0.04) and between stage II and III (median 81 vs. 62 months, P&lt;0.001). The UK staging system (NT-proBNP 3000 ng/L and eGFR 45 mL/min), discriminated three groups [stage I: 170 (45%), stage II: 165 (43%) and stage III: 45 (12%)] with a significant difference in survival: between stage I and stage II (86 vs. 52 months, P&lt;0.001) and between stage II and stage III (median survival 52 vs. 33 months, P=0.045). Conclusions This is one of the largest series of patients with cardiac ATTRwt reported so far. Referrals and diagnoses increased exponentially in recent years, One-third of patients has a concomitant monoclonal gammopathy and needed tissue typing. Both the current staging systems offered good discrimination of staging and were validated in our independent cohort. Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document